2019 Biomedtracker / Datamonitor Healthcare Post-ASCO Report
2019 Biomedtracker / Datamonitor Healthcare Post-ASCO Report
$2,995.00
Publisher: Datamonitor Healthcare
- Highlights
- Description
- Contents
The 55th Annual Meeting of the American Society of Clinical Oncology (ASCO) was held in Chicago, IL from May 31st through June 4th, 2019. This year’s conference was highly varied, with key data presented for drugs in numerous different classes and indications. Highlights included new data for Kisqali in HR+/HER2- breast cancer, Xtandi in prostate cancer, Lynparza in pancreatic cancer, and AMG510 in KRAS mutation-positive solid tumors. As with the past several years, PD-1/PD-L1 inhibitors were also featured prominently, with products like Keytruda, Opdivo, and Tecentriq each being included in multiple presentations. CAR-T therapies also remained in the spotlight, with this year’s conference showing their future potential in solid tumor indications.
This post-meeting report features commentary from our analysts on key presentations given at the conference as well as a compilation of all data events added to Biomedtracker in conjunction with the meeting
Overview
The 55th Annual Meeting of the American Society of Clinical Oncology (ASCO) was held in Chicago, IL from May 31st through June 4th, 2019. This year’s conference was highly varied, with key data presented for drugs in numerous different classes and indications. Highlights included new data for Kisqali in HR+/HER2- breast cancer, Xtandi in prostate cancer, Lynparza in pancreatic cancer, and AMG510 in KRAS mutation-positive solid tumors. As with the past several years, PD-1/PD-L1 inhibitors were also featured prominently, with products like Keytruda, Opdivo, and Tecentriq each being included in multiple presentations. CAR-T therapies also remained in the spotlight, with this year’s conference showing their future potential in solid tumor indications.
This post-meeting report features commentary from our analysts on key presentations given at the conference as well as a compilation of all data events added to Biomedtracker in conjunction with the meeting.
Contents
Meeting Overview………………………………………………………………………………………………………………………..6
Key Drug Analyses and Abstracts…………………………………………………………………………………………………….9
Acute Lymphocytic Leukemia (ALL)………………………………………………………………………………………………….9
Yescarta (GILD, Phase II)…………………………………………………………………………………………………………9
Acute Myelogenous Leukemia (AML)……………………………………………………………………………………………..10
CX-01 (Cantex Pharmaceuticals, Phase II) ……………………………………………………………………………….10
Tibsovo (AGIO, Approved)…………………………………………………………………………………………………….12
Bladder Cancer …………………………………………………………………………………………………………………………..14
Enfortumab Vedotin (Astellas, Phase III) …………………………………………………………………………………14
Brain Cancer (Malignant Glioma; AA and glioblastoma (GBM))…………………………………………………………..17
AG-881 (AGIO, Phase I) and Tibsovo (AGIO, Phase I)…………………………………………………………………17
DS-1001 (DSKYF, Phase I)………………………………………………………………………………………………………19
Breast Cancer……………………………………………………………………………………………………………………………..20
Capivasertib (AZN, Phase II)…………………………………………………………………………………………………..20
H3B-6545 (EASLY, Phase II)……………………………………………………………………………………………………22
Kisqali (NVS, Approved)………………………………………………………………………………………………………..23
Margetuximab (MDNX, Phase III) …………………………………………………………………………………………..25
Nerlynx (PBYI, Approved) ……………………………………………………………………………………………………..27
Perjeta (RHHBY, Approved) …………………………………………………………………………………………………..30
Talzenna (PFE, Approved)……………………………………………………………………………………………………..32
Cancer……………………………………………………………………………………………………………………………………….33
ADU-S100 (ADRO, Phase I) ……………………………………………………………………………………………………33
Cervical Cancer …………………………………………………………………………………………………………………………..35
LN-145 (IOVA, Phase II) ………………………………………………………………………………………………………..35
Venclexta (ABBV, Approved) …………………………………………………………………………………………………37
Diffuse Large B-Cell Lymphoma (DLBCL) – NHL ………………………………………………………………………………..39
Mosunetuzumab (RHHBY, Phase II)………………………………………………………………………………………..39
Gastric Cancer…………………………………………………………………………………………………………………………….41
Keytruda (MRK, Approved)……………………………………………………………………………………………………41
Cabometyx / Cometriq (EXEL, Investigator Initiated) ………………………………………………………………..44
Head and Neck Cancer…………………………………………………………………………………………………………………45
ASP-1929 (Rakuten Medical, Phase III)……………………………………………………………………………………45
Keytruda (MRK, Approved)……………………………………………………………………………………………………47
SD-101 (DVAX, Suspended) …………………………………………………………………………………………………..51
Hepatocellular (Liver) Cancer (HCC) (Including Secondary Metastases) ……………………………………………….52
Keytruda (MRK, Approved)……………………………………………………………………………………………………52
Melanoma …………………………………………………………………………………………………………………………………53
Contego (IOVA, Phase II) ………………………………………………………………………………………………………53
PDR001 (NVS, Phase III)………………………………………………………………………………………………………..55
Multiple Myeloma……………………………………………………………………………………………………………………….56
AMG 420 (AMGN, Phase II) …………………………………………………………………………………………………..56
Darzalex (JNJ, Approved)………………………………………………………………………………………………………58
Iberdomide (CELG, Phase II) ………………………………………………………………………………………………….60
Isatuximab (SNY, Phase III) ……………………………………………………………………………………………………62
Myelofibrosis (MF)………………………………………………………………………………………………………………………66
CPI-0610 (CNST, Phase II) ……………………………………………………………………………………………………..66
Fedratinib (CELG, NDA/BLA)………………………………………………………………………………………………….68
Non-Small Cell Lung Cancer (NSCLC)………………………………………………………………………………………………70
BLU-667 (BPMC, Phase I)………………………………………………………………………………………………………70
CAN04 (CANTA:SS, Phase II) ………………………………………………………………………………………………….73
Capmatinib (NVS, Phase II) ……………………………………………………………………………………………………75
TAK-788 (TAK, Phase II) ………………………………………………………………………………………………………..76
Tepotinib (MKGAY, Phase II)………………………………………………………………………………………………….79
Ovarian Cancer …………………………………………………………………………………………………………………………..81
Lynparza (AZN, Approved)…………………………………………………………………………………………………….81
Tivopath (Oncology) (AVEO, Phase II)……………………………………………………………………………………..82
XMT-1536 (MRSN, Phase I)……………………………………………………………………………………………………84
Pancreatic Cancer……………………………………………………………………………………………………………………….86
Abraxane (CELG, Approved) ………………………………………………………………………………………………….86
Lynparza (AZN, Phase III) ………………………………………………………………………………………………………87
Prostate Cancer ………………………………………………………………………………………………………………………….90
Darolutamide (BAYRY, NDA/BLA) …………………………………………………………………………………………..90
Erleada (JNJ, Approved)………………………………………………………………………………………………………..93
Lynparza (AZN, Phase III) ………………………………………………………………………………………………………96
Sagient Analysis American Society of Clinical Oncology (ASCO) 05/31/2019 (Abstract 5005)…………98
Xtandi (Astellas 4503:JP, Approved)……………………………………………………………………………………….98
Renal Cell Cancer (RCC)………………………………………………………………………………………………………………100
Tivopath (Oncology) (AVEO, Phase III)…………………………………………………………………………………..100
Sarcoma…………………………………………………………………………………………………………………………………..101
Lartruvo (LLY, Approved)…………………………………………………………………………………………………….101
NKTR-214 (NKTR, Investigator Initiated)………………………………………………………………………………..103
Tazemetostat (EPZM, NDA/BLA)…………………………………………………………………………………………..105
Small Cell Lung Cancer (SCLC) ……………………………………………………………………………………………………..107
Zepsyre (ZEL:SM, Phase III)………………………………………………………………………………………………….107
Solid Tumors…………………………………………………………………………………………………………………………….109
AMG 510 (AMGN, Phase I) ………………………………………………………………………………………………….109
Cymraza (LLY Phase II)………………………………………………………………………………………………………..110
Mesothelin-targeted CAR T Program (Atara) (ATRA, Phase I)……………………………………………………111
MORAb-202 (ESALY, Phase I)……………………………………………………………………………………………….114
mRNA-4157 (MRNA, Phase I) ………………………………………………………………………………………………115
NKTR-214 (NKTR, Phase II)…………………………………………………………………………………………………..116
Repotrectinib (TPTX, Phase II) ……………………………………………………………………………………………..119
List of Biomedtracker ASCO Events……………………………………………………………………………………………..123
© Pharma Intelligence UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Biosimilars in the US and Europe 
Sign up to the